Irit Avivi
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Oncology top 1%
- CAR-T cell therapy research
- Cancer Risks and Factors
Papers in
- Hematology 95
- Multiple Myeloma Research and Treatments 56
- Acute Myeloid Leukemia Research 20
- Genetics 53
- Chronic Lymphocytic Leukemia Research 40
- Co-authors
- Jacob M. RoweEldad J. DannRon EpelbaumBenjamin BrennerChava PerryNoam BenyaminiRon RamAnthony H. Goldstone
- Journals
- Blood (52 papers)British Journal of Haematology (13 papers)European Journal Of Haematology (11 papers)Annals of Hematology (10 papers)Haematologica (9 papers)
- Partner nations
- IsraelUnited StatesSpain
In The Last Decade
Irit Avivi
239 papers receiving 4.5k citations
Peers
Comparison fields: 5 of 115
- Hematology 1.0k
- Oncology 2.0k
- Pathology and Forensic Medicine 1.3k
- Genetics 582
- Immunology 740
Countries citing papers authored by Irit Avivi
This map shows the geographic impact of Irit Avivi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irit Avivi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irit Avivi more than expected).
Fields of papers citing papers by Irit Avivi
This network shows the impact of papers produced by Irit Avivi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irit Avivi. The network helps show where Irit Avivi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Irit Avivi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 6 | |
| 6 | 2023 | 6 | |
| 7 | 2023 | 10 | |
| 8 | 2023 | 4 | |
| 9 | 2022 | 2 | |
| 10 | 2022 | 21 | |
| 11 | 2021 | 0 | |
| 12 | 2021 | 46 | |
| 13 | 2020 | 2 | |
| 14 | 2020 | 8 | |
| 15 | 2020 | 1 | |
| 16 | 2019 | 30 | |
| 17 | 2018 | 8 | |
| 18 | 2017 | 17 | |
| 19 | 2017 | 2 | |
| 20 | 2013 | 70 |
About Irit Avivi
Irit Avivi is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Immunology, having authored 247 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (74 papers), Multiple Myeloma Research and Treatments (56 papers), Chronic Lymphocytic Leukemia Research (40 papers), CAR-T cell therapy research (35 papers), Protein Degradation and Inhibitors (23 papers), Acute Myeloid Leukemia Research (20 papers), Peptidase Inhibition and Analysis (19 papers) and Viral-associated cancers and disorders (18 papers). The work is most often cited by research in Hematology (1.0k citations), Oncology (2.0k citations), Pathology and Forensic Medicine (1.3k citations), Genetics (582 citations) and Immunology (740 citations). Irit Avivi has collaborated with scholars based in Israel, United States and Spain. Frequent co-authors include Jacob M. Rowe, Eldad J. Dann, Ron Epelbaum, Benjamin Brenner, Chava Perry, Noam Benyamini, Ron Ram, Anthony H. Goldstone, Rachel Bar‐Shalom and Michael Lishner. Their work appears in journals such as Blood, British Journal of Haematology, European Journal Of Haematology, Annals of Hematology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.